All Releases
 |
Aastrom Initiates IMPACT-DCM Extension Study for Control Patients
07-14-10
|
10.8 KB |
|
| |
ANN ARBOR, Mich., July 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in...
|
|
Aastrom to Pursue Phase 3 Clinical Program in CLI
07-06-10
|
12.3 KB |
|
| |
ANN ARBOR, Mich., July 6, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (...
|
|
Interim Results From Aastrom Critical Limb Ischemia Study Presented Today at Society for Vascular Surgery Annual Meeting
06-11-10
|
13.5 KB |
|
| |
ANN ARBOR, Mich., June 11, 2010 (GLOBE NEWSWIRE) -- Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH and a principal investigator of the U.S. Phase 2b RESTORE-CLI clinical trial sponsored by Aastrom Biosciences (Nasdaq:ASTM), will present the full results from the interim analysis ...
|
|
Scott C. Durbin Joins Aastrom as Chief Financial Officer
06-08-10
|
11.4 KB |
|
| |
ANN ARBOR, Mich., June 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Scott C. Durbin has joined the company as chief financial officer. Mr. Durbin brings more than 15 years of healthcare-related ba...
|
|
Webcast Alert: Aastrom to Host Investor Conference Call and Webcast on June 11, 2010 Following Presentation at Society for Vascular Surgery Meeting
06-04-10
|
11.3 KB |
|
| |
ANN ARBOR, Mich., June 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast:
What: Conference call and webcast of the presentation of interim results from Aastrom's U.S. Phase 2b RESTORE-CLI clinical trial which will be presented at the Vascular Annual Meeting® of the Society for Vascular Surgery. ...
|
|
Aastrom to Participate in First Annual Stem Cell Investor & Executive Networking Conference Event
05-27-10
|
12.1 KB |
|
| |
ANN ARBOR, Mich., May 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Ronnda Bartel, Ph.D., chief scientific officer, will participate in a plenary session at the first annual Stem Cell Investor & E...
|
|
Aastrom Announces Senior Management Appointments
05-20-10
|
11.8 KB |
|
| |
ANN ARBOR, Mich., May 20, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the appointments of Sharon Watling, Pharm.D., as vice president, clinical and regulatory, and Ronnda L. Bartel, Ph.D., formerly vice ...
|
|
First Patient Treated in Aastrom's U.S. Phase 2 Catheter Clinical Trial in Dilated Cardiomyopathy
05-17-10
|
13.0 KB |
|
| |
ANN ARBOR, Mich., May 17, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (...
|
|
Aastrom Reports Third Quarter Fiscal Year 2010 Financial Results
05-10-10
|
19.2 KB |
|
| |
ANN ARBOR, Mich., May 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical developmen...
|
|
Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress
05-03-10
|
10.4 KB |
|
| |
Ann Arbor, Michigan, May 3, 2010 (3:20 pm ET) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following webcast:
What:
Investor conference call to present an update on clinical development efforts related to critical limb is...
|
|
Interim Results From Aastrom's Vascular Trial to be Presented at Society for Vascular Surgery Annual Meeting
05-03-10
|
12.9 KB |
|
| |
ANN ARBOR, Mich., May 3, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that positive interim results from the company's U.S. Phase 2b trial designated RESTORE-CLI has been accepted for presentation at this...
|
|
Aastrom Announces Formation of Scientific Advisory Board
04-12-10
|
13.3 KB |
|
| |
ANN ARBOR, Mich., April 12, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the appointments of Daniel R. Salomon, M.D., Karen K. Hirschi, Ph.D., Marc Penn, M.D., Ph.D., FACC, and Mahendra Rao, M.D., Ph.D., to...
|
|
Aastrom Announces Treatment of Final Patient in RESTORE-CLI Clinical Trial
03-24-10
|
12.3 KB |
|
| |
ANN ARBOR, Mich., March 24, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company's ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase...
|
|
Aastrom Ticker Symbol Reverts to ASTM
03-18-10
|
10.0 KB |
|
| |
ANN ARBOR, Mich., March 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its ticker symbol will revert back to ASTM as of March 18, 2010. As a result of the company's reverse stock split which became effective as of February 18, 2010, the company's common stock had been trading on a post-split basis under th...
|
|
Aastrom Announces Treatment of Final Patient in IMPACT-DCM Surgical Clinical Trial
03-09-10
|
12.3 KB |
|
| |
ANN ARBOR, Mich., March 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM. Treated at Emory Univ...
|
|
Aastrom Regains Compliance With NASDAQ Minimum Bid Requirement
03-04-10
|
10.4 KB |
|
| |
ANN ARBOR, Mich., March 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule ...
|
|
Aastrom Reports Interim Results From Critical Limb Ischemia Trial
02-24-10
|
11.7 KB |
|
| |
Study meets composite endpoint of reduction in time to treatment failure with statistical significance Company concludes patient enrollment early to accelerate study completion and Phase 3 planning Aastrom to hold investor conference call at 9 a.m. ET to discuss results
ANN ARBOR, Mich., Feb. 24, 2010 (GLOBE NEWSWIRE) ...
|
|
Aastrom One-for-Eight Reverse Stock Split Now Effective
02-18-10
|
9.1 KB |
|
| |
ANN ARBOR, Mich., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its previously announced one-for-eight reverse stock split of the company's issued and outstanding common shares is now effective. This reverse split is intended to increase the per share trading price of Aastrom's common stock to satisf...
|
|
Aastrom Reports Second Quarter Fiscal Year 2010 Financial Results
02-10-10
|
19.1 KB |
|
| |
ANN ARBOR, Mich., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for its second fiscal quarter ended December 31, 2009, and also announced progress in its late-stage clinica...
|
|
Aastrom Announces One-for-Eight Reverse Stock Split
02-09-10
|
9.3 KB |
|
| |
ANN ARBOR, Mich., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announced today that its board of directors has approved a one-for-eight reverse stock split of the company's common stock effective on February 18, 2010. The company has filed an amendment to its articles of incorporation to effect the reverse stock split, which ...
|
|
|
